



**Universiteit
Leiden**
The Netherlands

A systematic evaluation of cost-saving dosing regimens for therapeutic antibodies and antibody-drug conjugates for the treatment of lung cancer

Heine, R. ter; Heuvel, M.M. van den; Piet, B.; Deenen, M.J.; Wekken, A.J. van der; Hendriks, L.E.L.; ... ; Rouw, N. de

Citation

Heine, R. ter, Heuvel, M. M. van den, Piet, B., Deenen, M. J., Wekken, A. J. van der, Hendriks, L. E. L., ... Rouw, N. de. (2023). A systematic evaluation of cost-saving dosing regimens for therapeutic antibodies and antibody-drug conjugates for the treatment of lung cancer. *Targeted Oncology*, 18(3), 441-450. doi:10.1007/s11523-023-00958-6

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3638687>

Note: To cite this publication please use the final published version (if applicable).



A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

Rob ter Heine¹ · Michel M. van den Heuvel² · Berber Piet² · Maarten J. Deenen^{3,4} · Anthonie J. van der Wekken⁵ · Lizza E. L. Hendriks⁶ · Sander Croes^{7,8} · Robin M. J. M. van Geel^{7,8} · Frank G. A. Jansman^{9,10} · Rogier C. Boshuizen¹¹ · Eric J. F. Franssen¹² · Arthur A. J. Smit¹³ · Daphne W. Dumoulin¹⁴ · Thijs H. Oude Munnink¹⁵ · Egbert F. Smit¹⁶ · Hieronymus J. Derijks^{1,17} · Cor H. van der Leest¹⁸ · Jeroen J. M. A. Hendriks¹⁹ · Dirk J. A. R. Moes²⁰ · Nikki de Rouw^{1,21}

Accepted: 15 March 2023 / Published online: 21 April 2023
© The Author(s) 2023

Abstract

Background Expensive novel anticancer drugs put a serious strain on healthcare budgets, and the associated drug expenses limit access to life-saving treatments worldwide.

Objective We aimed to develop alternative dosing regimens to reduce drug expenses.

Methods We developed alternative dosing regimens for the following monoclonal antibodies used for the treatment of lung cancer: amivantamab, atezolizumab, bevacizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and ramucirumab; and for the antibody-drug conjugate trastuzumab deruxtecan. The alternative dosing regimens were developed by means of modeling and simulation based on the population pharmacokinetic models developed by the license holders. They were based on weight bands and the administration of complete vials to limit drug wastage. The resulting dosing regimens were developed to comply with criteria used by regulatory authorities for in silico dose development.

Results We found that alternative dosing regimens could result in cost savings that range from 11 to 28%, and lead to equivalent pharmacokinetic exposure with no relevant increases in variability in exposure.

Conclusions Dosing regimens based on weight bands and the use of complete vials to reduce drug wastage result in less expenses while maintaining equivalent exposure. The level of evidence of our proposal is the same as accepted by regulatory authorities for the approval of alternative dosing regimens of other monoclonal antibodies in oncology. The proposed alternative dosing regimens can, therefore, be directly implemented in clinical practice.

Key Points

The high expenses for lung cancer drugs limit the access to innovative treatments worldwide.

Alternative dosing regimens for amivantamab, atezolizumab, bevacizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, ramucirumab, and trastuzumab deruxtecan have the potential to save up to approximately 30% in drug expenses without predicted loss in effective exposure.

The level of evidence for these alternative dosing regimens is the same as accepted by regulatory authorities, facilitating their direct implementation.

1 Introduction

Lung cancer is one of the most common cancers, with more than 2 million new cases and 1.8 million deaths reported in 2020 [1]. In the last decade, the development of novel systemic treatments, such as immune checkpoint inhibitors and targeted therapies, has majorly improved treatment outcomes of locally advanced and metastatic lung cancer [2]. For non-small cell lung cancer, these drugs are now also moving to the early disease setting. However, these advances are associated with a serious price tag. The ever-increasing cancer drug prices are already straining healthcare budgets and they present serious hurdles to treatment access worldwide [3]. It is, therefore, of utmost importance to save treatment costs whenever possible. For cancer drugs, there is often considerable drug waste due to drug spill of partially used vials [4]. Additionally, several monoclonal antibodies are dosed within the linear milligram per kilogram bodyweight (mg/

✉ Rob ter Heine
r.terheine@radboudumc.nl

Extended author information available on the last page of the article

kg) paradigm. Because of the well-established non-linear relationship between body weight and systemic exposure to monoclonal antibodies, a linear mg/kg dosing approach will result in unnecessary pharmacokinetic variability [5, 6]. Therefore, dosing regimens accounting for this non-linear relationship have the potential to partly decrease pharmacokinetic variability.

The use of modeling and simulation to develop alternative dosing regimens for monoclonal antibodies has been embraced by the medical community [7], pharmaceutical companies [8, 9], and regulatory authorities [10]. This approach has, thus far, been employed to develop fixed dosing regimens and prolonged dosing intervals for the purposes of patient and prescriber convenience. This generally results in higher cumulative doses than initially approved [11, 12]. However, modeling and simulation can also be applied to develop cost-effective and clinically equivalent dosing regimens while limiting cumulative drug use.

Using the same approach that led to label changes of marketed monoclonal antibodies approved by the European Medicines Agency and the US Food and Drug Administration (FDA), we present alternative dosing regimens for currently approved monoclonal antibodies and antibody-drug conjugates for the treatment of lung cancer to reduce drug expenses, while maintaining equivalent systemic drug exposure, as a direct indicator for clinical response.

2 Methods

2.1 Drug Selection

The following drugs were included in this study: amivantamab, atezolizumab, bevacizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, ramucirumab, and trastuzumab deruxtecan. Cemiplimab was excluded from this study, as only a single vial size is available containing exactly the dose to be administered, hampering further dose optimization, in contrast to the other drugs where vial sizes smaller than the approved dose were available.

2.2 Pharmacokinetic Modeling

We used the population pharmacokinetic models as developed in representative cancer populations by the license holders and that were published in peer-reviewed scientific articles or in the drug approval data (see Table 1). The model code was verified by two experienced modelers. Then, for each individual drug, we performed a Monte Carlo simulation using the non-linear mixed-effects modeling software package NONMEM Version 7.5 (Icon, Dublin, Ireland) of the dosing regimens used in the pivotal phase III trials for registration. For this purpose, we

created 500 virtual patients with representative European demographic data from the International Cancer Research Partnership database from the PopGen virtual human population generator [13]. The median total body weight of this population was 68 kg, with an interquartile range of 57–78 kg (total range 31–128 kg). Covariate distributions were simulated as reported for the populations of the published population pharmacokinetic models from the reported mean or median and corresponding variability. The pharmacokinetic data obtained from our simulations with the pivotal phase III dose were then considered as the reference for alternative dosing regimens. Thereafter, for each drug, we developed a weight band-based dosing regimen with the same dosing interval, based on both the available vial sizes and the described relationship between body size and pharmacokinetics. All simulations were performed in compliance with the recently published FDA guideline describing pharmacokinetic-based criteria to develop alternative dosing regimens for programmed cell death-1- or ligand-1-blocking antibodies [10]. This guideline states that the geometric mean of the area under the concentration–time curve during a dosing interval and the geometric mean concentration at steady state (AUC_{ss} and $C_{trough,ss}$) and/or at the end of the first dosing cycle ($AUC_{ss,1st}$ and $C_{trough,1st}$) are no more than 20% lower or higher compared with the reference dosing regimen. Furthermore, the maximum concentration (C_{max}) at steady state should not increase more than 20% compared with that of the reference dosing regimen.

As a clear dose– and exposure–response relationship has been reported for ipilimumab, leading to less efficacy at a lower exposure and dose and more toxicity at a higher exposure and dose [14, 15], the alternative ipilimumab dose to be developed was chosen to match the reference pharmacokinetics as closely as possible. For all other drugs, an alternative dosing regimen was developed leading to an exposure lower than associated with the reference dose, but within the margins of equivalence (a < 20% difference in relevant pharmacokinetic endpoints). Furthermore, separate alternative dosing regimens were evaluated for nivolumab every 2 weeks (Q2W) and every 3 weeks (Q3W). Initially, nivolumab was approved in a 3-mg/kg Q2W dose [16]. Recently, the combination of nivolumab and ipilimumab with two cycles of chemotherapy was approved based on the results of the CHECKMATE-9LA phase III trial, where nivolumab was dosed in a flat, fixed, 360-mg Q3W dose [17]. As chemotherapy is administered in Q3W cycles, an alternative Q3W dosing regimen was developed as well for nivolumab.

The alternative dosing regimens were based on the established relationship between body size and pharmacokinetics in the selected population pharmacokinetic models, to prevent a systematic bias of drug exposure

Table 1 Description of drugs

Drug	Reference dose and dosing interval	Alternative approved dose based on modeling and simulation by license holder	Available vial sizes	Population pharmacokinetic model source	Covariates in the pharmacokinetic model
Amivantamab	1050 mg < 80 kg bodyweight 1400 mg ≥ 80 kg bodyweight Q1W for 4 weeks, Q2W thereafter [18]	–	350 mg	FDA drug approval package [19]	Body weight
Atezolizumab	1200 mg Q3W [20]	840 mg Q2W 1680 mg Q4W [20, 21]	840 mg, 1200 mg	FDA drug approval package [22]	Body weight Sex Tumor burden Albumin Antidrug antibodies
Bevacizumab	15 mg/kg Q3W [23]	–	100 mg, 400 mg	Han et al. [24]	Albumin Alkaline phosphatase Sex Body weight
Durvalumab	10 mg/kg Q2W [25] 20 mg/kg Q4W [25]	1500 mg Q4W (> 30 kg) [11] [Q3W during 4 cycles when combined with chemotherapy]	120 mg, 500 mg	Baverel et al. [11]	Albumin Creatinine clearance Sex Performance status Tumor size Soluble PD-L1
Ipilimumab	1 mg/kg Q6W [26]	–	50 mg, 200 mg	Sanghavi et al. [27]	Body weight Lactate dehydrogenase Tumor type Combination therapy
Nivolumab Q2W and Q4W	3 mg/kg Q2W [16]	240 mg Q2W [28] 480 mg Q4W [29]	40 mg, 100 mg, 120 mg, 240 mg	Zhang et al. [30]	Body weight Age Glomerular filtration rate Lactate dehydrogenase Albumin Sex Performance status Tumor type Line of therapy Chemotherapy
Nivolumab Q3W	360 mg Q3W [17]	–			
Pembrolizumab	2 mg/kg Q3W [31]	200 mg Q3W [9] 400 mg Q6W [12]	100 mg	Ahamadi et al. [32]	Albumin Glomerular filtration rate Tumor size Performance status Indication Sex Body weight
Ramucirumab	10 mg/kg Q2W [33]	–	100 mg, 500 mg	O'Brien et al. [34]	Body weight
Trastuzumab derux-tecan	5.4 mg/kg Q3W [35]	–	100 mg	Yin et al. [36]	Albumin Tumor size Body weight

FDA Food and Drug Administration, PD-L1 programmed cell death ligand 1, Q1W every week, Q2W every 2 weeks, Q3W every 3 weeks, Q4W every 4 weeks, Q6W every 6 weeks

versus body size. Furthermore, the alternative dosing regimens were based on the available vial sizes to prevent wastage as much as possible. From our simulations, we

derived the geometric mean of the AUC during a dosing interval and the C_{trough} (and the corresponding geometric coefficient of variation) of the selected drugs at the first

cycle and at steady state. Moreover, for both dosing scenarios, the average quantity of drug used per dose administered was calculated, assuming wastage of the remainder of the smallest vial size available when it was partially used. The potential savings compared to dosing regimens in the drug labels were then calculated. The code for all pharmacokinetic models used for modeling and simulation is supplied in the Electronic Supplementary Material of this article as a reference. Table 1 describes the selected drugs, the dosing regimens from the pivotal phase III trial used as the reference dose, the reported approved alternative dosing regimens already developed by the license holders based on modeling and simulation, as well as the available vial sizes and the source for the population pharmacokinetic models.

3 Results

The results of our study are presented in Table 2. All predicted C_{trough} or AUC from the alternative dose deviated were within $\pm 20\%$ from the reference dose, as all ratios for these pharmacokinetic endpoints for the alternative and reference dose fell within the 0.8–1.2 boundaries for pharmacokinetic equivalence. For ipilimumab, no difference in predicted exposure was observed in the alternative dose. Furthermore, the predicted variability in C_{trough} and AUC of the alternative dosing regimens was similar to that of the reference dosing regimens, showing that weight-band dosing does not relevantly increase variability in drug exposure. As no AUC or dose on the population was higher than associated with the reference dosing regimen, none of the C_{max} of the alternative dosing regimens deviated $> 20\%$ from the C_{max} from the reference dosing regimens for the population (data not shown).

As observed in Table 2, all alternative dosing regimens resulted in equivalent exposures with a $< 20\%$ difference in both the geometric means of C_{trough} and AUC during a dosing interval after the first cycle and at steady state (calculated ratios within the predefined 0.8–1.2 boundaries), with maximum average savings in expenses compared with the reference dose that range from 28% (trastuzumab deruxtecan) to 11% (pembrolizumab).

The reductions in the average quantity of drug used in our proposed alternative dosing regimens are driven both by lower doses and rounding of the dose based on weight bands. For pembrolizumab, we propose a dose of either 100 or 150 mg for people weighing < 60 or > 60 kg, respectively. As only 100-mg vials exist for pembrolizumab, the preparation of a 150-mg dose results in a projected wastage of two vials. We predicted savings of approximately 11% for the alternative dose of pembrolizumab compared with the reference dose of 2 mg/

kg. Compared to the currently approved 200-mg Q3W and 400-mg Q6W doses, the projected savings increase to 16%. As pembrolizumab is currently one of the most frequently used programmed cell death-1 inhibitors, we think that the actual savings in drug expenses will be higher, as vial sharing will further reduce wastage. The manufacturer of pembrolizumab has recently shown that pembrolizumab infusions are stable for at least 1 week after reconstitution, further facilitating paring of preparations for multiple patients to prevent wastage when appropriate microbiological conditions are met [37]. The 400-mg Q6W dosing regimen for pembrolizumab has been approved based on modeling and simulation with the 2-mg/kg Q3W dosing regimen as the reference. It was shown that in the Q6W dosing regimen, the C_{trough} was 12% lower than the C_{trough} associated with the initially approved 2-mg/kg Q3W dosing interval [12]. This shows that further dose reductions for a Q6W dosing regimen of pembrolizumab are not possible without violating the proposed criteria for equivalence.

4 Discussion

In our analysis, we calculated the maximum fraction of drug saved by our alternative dosing regimen compared to the reference dosing regimen. However, for durvalumab and nivolumab, the savings compared with the currently approved dosing regimens may be even higher. Although the durvalumab dosing regimen of 10 mg/kg Q2W was used in the phase III clinical study that led to its approval, the license holder has changed the label to a 1500-mg Q4W dosing regimen based on modeling and simulation. This may facilitate additional savings. For patients weighing < 60 kg, we propose a 480-mg Q2W dose (corresponding with a 960-mg cumulative dose during a 4-week interval), which results in 36% savings in drug costs compared with the approved 1500-mg Q4W dose. For the nivolumab 240-mg Q2W and 480-mg Q4W dosing regimens, which were developed by the license holder based on modeling and simulation after initial approval of the 3-mg/kg Q2W dose, the savings generated by our alternative dosing regimen for nivolumab may be up to 50% compared with the fixed-dose regimens, depending on the weight of the patient.

Our simulations were based on a representative European population. In a population with a higher average body weight, the average administered dose will be higher. Nonetheless, our proposed alternative dosing regimens, based on weight bands, may still result in reductions in drug expenses compared with the reference dosing regimens in populations with a higher body weight.

Table 2 Summary of results

Drug and dosing regimen	Geometric mean $C_{trough \cdot 1st}$ (%CV)	Geometric mean $C_{trough \cdot ss}$ (%CV)	Geometric mean AUC_{1st} (%CV)	Geometric mean AUC_{ss} (%CV)	Average quantity of drug used per dose ^a
<i>Amivantamab Q2W</i>					
<u>Reference dose</u> < 80 kg: 1050 mg ≥ 80 kg: 1400 mg	131 mg/L (28%)	134 mg/L (73%)	26,742 mg·h/L (26%)	79,735 mg·h/L (41%)	1126 mg
<u>Alternative dose</u> <60 kg: 700 mg 60–100 kg: 1050 mg >100 kg: 1400 mg	109 mg/L (27%)	112 mg/L (67%)	22,270 mg h/L (27%)	66,399 mg·h/L (37%)	949 mg
Ratio alternative:reference	0.83	0.83	0.83	0.83	0.84
<i>Atezolizumab Q3W</i>					
<u>Reference dose</u> 1200 mg	89 mg/L (28%)	209 mg/L (48%)	3247 mg·day/L (19%)	6707 mg·day/L (33%)	1200 mg
<u>Alternative dose</u> < 70 kg: 840 mg ≥ 70 kg: 1200 mg	74 mg/L (29%)	172 mg/L (44%)	2669 mg·day/L (22%)	5528 mg·day/L (31%)	1005 mg
Ratio alternative:reference	0.82	0.82	0.82	0.82	0.84
<i>Bevacizumab Q3W</i>					
<u>Reference dose</u> 15 mg/kg	62 mg/L (35%)	114 mg/L (50%)	62,824 mg·h/L (21%)	104,111 mg·h/L (31%)	1075 mg
<u>Alternative dose</u> < 55 kg: 700 mg 55–70 kg: 800 mg 70–100 kg: 1000 mg > 100 kg: 1200 mg	54 mg/L (34%)	99 mg/L (51%)	54,650 mg·h/L (19%)	90,826 mg·h/L (31%)	875 mg
Ratio alternative:reference	0.87	0.87	0.87	0.87	0.81
<i>Durvalumab Q2W</i>					
<u>Reference dose</u> 10 mg/kg	51 mg/L (34%)	142 mg/L (51%)	1278 mg·day/L (24%)	2913 mg·day/L (38%)	745 mg
<u>Alternative dose</u> < 60 kg: 480 mg 60–80 kg: 600 mg > 80 kg: 720 mg	44 mg/L (32%)	123 mg/L (50%)	1117 mg·day/L (21%)	2544 mg·day/L (36%)	588 mg
Ratio alternative:reference	0.87	0.87	0.87	0.87	0.79
<i>Durvalumab Q4W</i>					
<u>Reference dose</u> 20 mg/kg	63 mg/L (42%)	112 mg/L (62%)	3740 mg·day/L (26%)	6025 mg·day/L (38%)	1423
<u>Alternative dose</u> < 60 kg: 960 mg 60–80 kg: 1200 mg > 80 kg: 1440 mg	54 mg/L (42%)	97 mg/L (62%)	3269 mg·day/L (24%)	5261 mg·day/L (37%)	1176
Ratio alternative:reference	0.87	0.87	0.87	0.87	0.83
<i>Ipilimumab Q6W</i>					
<u>Reference dose</u> 1 mg/kg	1.0 mg/L (71%)	2.1 mg/L (75%)	4013 mg·h/L (27%)	5998 mg·h/L (35%)	95 mg
<u>Alternative dose</u> < 60 kg: 50 mg 60–90 kg: 75 mg > 90 kg: 100 mg	1.0 mg/L (72%)	2.1 mg/L (75%)	4071 mg·h/L (28%)	6084 mg·h/L (36%)	84 mg
Ratio alternative:reference	1.0	1.0	1.0	1.0	0.88
<i>Nivolumab Q2W</i>					
<u>Reference dose</u> 3 mg/kg	10.4 mg/L (29%)	26.5 mg/L (38%)	6581 mg·h/L (25%)	13784 mg·h/L (27%)	224 mg

Table 2 (continued)

Drug and dosing regimen	Geometric mean $C_{trough,1st}$ (%CV)	Geometric mean $C_{trough,ss}$ (%CV)	Geometric mean AUC_{1st} (%CV)	Geometric mean AUC_{ss} (%CV)	Average quantity of drug used per dose ^a
<u>Alternative dose</u> < 50 kg: 120 mg 50–75 kg: 160 mg 75–100 kg: 200 mg > 100 kg: 240 mg	9.3 mg/L (33%)	24.2 mg/L (46%)	5758 mg·h/L (24%)	12388 mg·h/L (31%)	169 mg
Ratio alternative:reference	0.90	0.91	0.87	0.90	0.75
<i>Nivolumab Q3W</i>					
<u>Reference dose</u> 360 mg	16.7 mg/L (51%)	47.5 mg/L (77%)	17,126 mg·h/L (33%)	38,070 mg·h/L (51%)	360 mg
<u>Alternative dose</u> < 60 kg: 280 mg 60–90 kg: 320 mg > 90 kg: 360 mg	13.8 mg/L (52%)	38.5 (75%)	14,203 mg·h/L (30%)	31,197 mg·h/L (48%)	310 mg
Ratio alternative:reference	0.82	0.81	0.83	0.82	0.86
<i>Pembrolizumab Q3W</i>					
<u>Reference dose</u> 2 mg/kg	9.44 mg/L (30%)	23.0 (52%)	325 mg·day/L (26%)	708 mg·day/L (40%)	189 mg
<u>Alternative dose</u> < 60 kg: 100 mg > 60 kg: 150 mg	9.37 mg/L (30%)	22.9 mg/L (52%)	322 mg·day/L (26%)	703 mg·day/L (40%)	168 mg
Ratio alternative:reference	1.0	1.0	1.0	1.0	0.89
<i>Ramucirumab Q2W</i>					
<u>Reference dose</u> 10 mg/kg	37 mg/L (40%)	67 mg/L (49%)	1208 mg·day/L (27%)	1867 mg·day/L (33%)	734 mg
<u>Alternative dose</u> < 60 kg: 500 mg 60–80 kg: 600 mg 80–110 kg: 700 mg > 110 kg: 800 mg	32 mg/L (37%)	59 mg/L (47%)	1067 mg·day/L (23%)	1649 mg·day/L (31%)	591 mg
Ratio alternative:reference	0.88	0.88	0.88	0.88	0.81
<i>Trastuzumab deruxtecan Q3W</i>					
<u>Reference dose</u> 5.4 mg/kg	4.8 mg/L (64%)	10 mg/L (57%)	568 mg·day/L (25%)	725 mg·day/L (30%)	419 mg
<u>Alternative dose</u> < 45 kg: 200 mg 45–90 kg: 300 mg > 90 kg: 400 mg	4.0 mg/L (63%)	8.4 mg/L (57%)	476 mg·day/L (23%)	607 mg·day/L (29%)	302 mg
Ratio alternative:reference	0.84	0.84	0.84	0.84	0.72

AUC_{1st} , AUC_{ss} , $C_{trough,1st}$, $C_{trough,ss}$, CV coefficient of variation, Q2W every 2 weeks, Q3W every 3 weeks, Q4W every 4 weeks, Q6W every 6 weeks

^aThe average quantity of drug used per dose administered, assuming wastage of the smallest vial size available when partially used

In contrast to the other drugs in our analysis, trastuzumab is an antibody conjugated with the cytotoxic drug deruxtecan, which is a topoisomerase inhibitor [36]. As it is known that the pharmacokinetics of the (release of the) payload of trastuzumab deruxtecan is described by a linear pharmacokinetic process, the pharmacokinetics of the payload is directly proportional to the complete conjugate. Therefore, the pharmacokinetics of the complete conjugate was used as an endpoint for our investigation of alternative dosing regimens [36]. The approved linear (mg/kg) dosing regimen of trastuzumab deruxtecan leads

to relative overdosing in patients with a relatively higher weight, owing to the non-linear relationship between antibody clearance and body size [5]. For non-conjugated monoclonal antibodies, if complete receptor occupancy is reached in the approved dose across the complete range of body weights, relative overdosing will not result in toxicity. However, relative overdosing may result in additional toxicity for antibody-drug conjugates, as more of cytotoxic drug will also reach the systemic circulation. In the proposed alternative dose for trastuzumab deruxtecan, we accounted for the non-linear relationship between body

size and drug clearance, resulting in less relative overdosing in the higher weight range. Whether this also results in less toxicity should be prospectively verified, but seems plausible. No alternative dosing regimen could be developed for cemiplimab because of the limitations of a single vial size of 350 mg. The flat fixed 350-mg Q3W dose was based on modeling and simulation and based on a 3-mg/kg Q2W dosing regimen [38]. The development of smaller vial sizes (e.g., 50 and 100 mg), either by the manufacturer or by a public initiative, may have the potential to vastly reduce drug expenses.

There are some studies that indicate that nivolumab may be dosed lower than proposed by use here [39, 40], yet results are conflicting and higher doses of nivolumab appear to be required for the treatment of lung cancer [41–43]. Although we specifically focused on monoclonal antibodies and antibody-drug conjugates used for the treatment of lung cancer, most drugs in our analysis have broader indications. We propose that the developed alternative dosing regimens may be extrapolated to other indications for which these drugs are used, when the approved doses for lung cancer and the alternative indication are the same.

Our analysis was mainly focused on savings in drug expenses. However, total costs of treatment depend on more than drug expenses only. Some of the reference dosing regimens in our study (e.g., durvalumab) require more frequent (Q2W) administration than also described in the label (Q4W). More frequent administration may result in additional costs associated with preparation and administration of the drug. Furthermore, with regard to patient convenience, it may be argued that less frequent dosing may be more desirable as hospital visits will be reduced. Our analysis can be used to carefully weigh all these considerations to establish a cost-effective treatment for lung cancer. Another factor that should be weighed is that the pharmaceutical sector is responsible for a significant proportion of all carbon emissions [44]. By development of more sustainable dosing strategies with less drug wastage as presented here, one can directly contribute to the reduction of the carbon footprint of pharmaceuticals.

The criteria for a clinically equivalent exposure used in our analysis were derived from the FDA guideline for in silico dose development for programmed cell death-1 and programmed cell ligand-1 inhibitors [10], but some drugs (amivantamab, bevacizumab, ipilimumab, ramucirumab, and trastuzumab deruxtecan) in our study do not belong to these classes of drugs. However, we postulate that this FDA guidance may be applicable to other classes of therapeutic antibodies as well. We propose that if it is known that additional variability in exposure may cause relevant changes in the benefit-to-risk ratio of a drug (e.g., as with ipilimumab) [14, 15], stricter criteria should be used, for example: a maximum deviation of 10% in C_{trough} ,

C_{max} , and AUC and no increase in the variability of these pharmacokinetic endpoints. Our alternative dosing regimen for ipilimumab complies with these stricter criteria, while resulting in less drug wastage.

Although our alternative dosing regimens contribute to less drug expenses in the short term, we argue that high drug costs are symptoms of an underlying drug pricing system that should be fixed, for example by implementing pricing transparency [45]. Our proposal should be considered a “free-market solution” for a “free-market problem,” which can be used to limit drug expenses until we fundamentally change how the development of innovative drugs is funded and reimbursed.

5 Conclusions

We have developed alternative dosing regimens that will result in a reduction in drug wastage while maintaining clinically equivalent drug exposures, based on solid clinical pharmacological data from the license holders of the drugs. These dosing regimens may aid the reduction in costs and drug wastage without impacting drug efficacy and safety and may be implemented in routine practice without the necessity of performing an additional clinical study.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11523-023-00958-6>.

Author contributions Rob ter Heine designed the study, performed the analysis and wrote the manuscript. Dirk Jan A.R. Moes and Nikki de Rouw performed the analysis, checked the model code and wrote the manuscript. Michel M. van den Heuvel, Berber Piet, Maarten J. Deenen, Anthonie J. van der Wekken, Lizza E.L. Hendriks, Sander Croes, Robin M.J.M. van Geel, Frank G.A. Jansman, Rogier C. Boshuizen, Eric J. Franssen, Arthur J. Smit, Daphne W. Dumoulin, Thijs H. Oude Munnink, Egbert F. Smit, Hieronymus J. Derijks, Cor H. van der Leest and Jeroen J.M.A. Hendriks interpreted the data and results and wrote the manuscript.

Declarations

Funding No external funding was used in the preparation of this article.

Conflict of interest Rob ter Heine has received fees or funding from Stichting Treatmeds and Amgen. Anthonie van der Wekken has received fees or funding from AstraZeneca, Boehringer Ingelheim, Pfizer Roche, Takeda, Janssen Cilag, Lilly, and Merck. Michel van den Heuvel has received fees or funding from Amgen, Astrazeneca, BMS, Janssen Pharmaceutica, Stichting Treatmeds, Merck, MSD, Novartis, Pamgene, Pfizer, Roche, Roche diagnostics, Abbvie, Astrazeneca, BMS, Lilly, MSD, Novartis, Pfizer, and Roche. Daphne Dumoulin has received funding from Roche, BMS, MSD, Astra Zeneca, Amgen, and Pfizer. Cor van der Leest has received fees or funding from BMS and MSD en Janssen. Lizza Hendriks has received fees or funding from Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Pfizer, Benecke, Medtalks, VJOnology, high5oncology, BMS, Eli

Lilly, Takeda, MSD, Merck, Novartis, Amgen, and Janssen. Sander Croes, Robin van Geel, Frank Jansman, Rogier Boshuizen, Egbert Smit, Arthur Smit, Thijs Oude Munnink, Hieronymus Derijks, Jeroen Hendriks, Dirk Jan Moes, and Nikki de Rouw have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Availability of data and material All model files to generate the presented data are provided in the Electronic Supplementary Material.

Code availability Not applicable.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71:209–49.
- Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. *JAMA.* 2019;322:764–74.
- Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An arm and a leg: the rising cost of cancer drugs and impact on access. *Am Soc Clin Oncol Educ Book.* 2021;41:1–12.
- Liran O, Prus J, Gordon N, Almog V, Gruenewald T, Goldstein DA. A real-world analysis of cancer drug wastage due to oversized vials. *J Am Pharm Assoc.* 2018;58:643–6.
- Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. *Clin Pharmacokinet.* 2012;51:119–35.
- Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. *Annu Rev Pharmacol Toxicol.* 2008;48:303–32.
- Hendriks J, Haanen J, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. *Oncologist.* 2017;22:1212–21.
- Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. *Ann Oncol.* 2017;28:2002–8.
- Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. *J Immunother Cancer.* 2017;5:43.
- US FDA. Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry. 05-01-2023. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor>. Accessed 4 Apr 2023.
- Baverel PG, Dubois VFS, Jin CY, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. *Clin Pharmacol Ther.* 2018;103:631–42.
- Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. *Eur J Cancer.* 2020;131:68–75.
- McNally K, Cotton R, Hogg A, Loizou G. PopGen: a virtual human population generator. *Toxicology.* 2014;315:70–85.
- Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. *Clin Cancer Res.* 2013;19:3977–86.
- Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol.* 2010;11:155–64.
- EMA. Opdivo CHMP assessment report. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/assessment-report/opdivo-epar-public-assessment-report_en.pdf. Accessed 4 Apr 2023.
- Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22:198–211.
- EMA. Rybrevant CHMP assessment report. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/assessment-report/rybrevant-epar-public-assessment-report_en.pdf. Accessed 4 Apr 2023.
- FDA. Drug approval package: RYBREVANT. 02-11-2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761210Orig1s000TOC.cfm. Accessed 4 Apr 2023.
- EMA. Tecentriq CHMP assessment report. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/assessment-report/tecentriq-epar-public-assessment-report_en.pdf. Accessed 4 Apr 2023.
- Morrissey KM, Marchand M, Patel H, et al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. *Cancer Chemother Pharmacol.* 2019;84:1257–67.
- US FDA. Drug approval package: TECENTRIQ. 02-11-2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000TOC.cfm. Accessed 4 Apr 2023.
- EMA. Avastin scientific discussion. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/scientific-discussion/avastin-epar-scientific-discussion_en.pdf. Accessed 4 Apr 2023.
- Han K, Peyret T, Marchand M, et al. Population pharmacokinetics of bevacizumab in cancer patients with external validation. *Cancer Chemother Pharmacol.* 2016;78:341–51.
- EMA. Imfinzi CHMP assessment report. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/assessment-report/imfinzi-epar-public-assessment-report_en.pdf. Accessed 4 Apr 2023.
- EMA. Yervoy summary of product characteristics. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Accessed 4 Apr 2023.
- Sanghavi K, Zhang J, Zhao X, et al. Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with

- advanced solid tumors. *CPT Pharmacometrics Syst Pharmacol*. 2020;9:29–39.
28. Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. *Ann Oncol*. 2017;28:2002–8.
 29. Long G, Tykodi S, Schneider J, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. *Ann Oncol*. 2018;29:2208–13.
 30. Zhang J, Sanghavi K, Shen J, et al. Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies. *CPT Pharmacometrics Syst Pharmacol*. 2019;8:962–70.
 31. EMA. Keytruda CHMP assessment report. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/assessment-report/keytruda-epar-public-assessment-report_en.pdf. Accessed 4 Apr 2023.
 32. Ahamadi M, Freshwater T, Prohn ME, et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti–PD-1 monoclonal antibody in advanced solid tumors. *CPT Pharmacometr Syst Pharmacol*. 2017;6:49–57.
 33. EMA. Cyramza CHMP assessment report. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/assessment-report/cyramza-epar-public-assessment-report_en.pdf. Accessed 4 Apr 2023.
 34. O'Brien L, Westwood P, Gao L, Heathman M. Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. *Br J Clin Pharmacol*. 2017;83:2741–51.
 35. EMA. Enhertu CHMP assessment report. 02-11-2022. Available from: https://www.ema.europa.eu/en/documents/assessment-report/enhertu-epar-public-assessment-report_en.pdf. Accessed 4 Apr 2023.
 36. Yin O, Xiong Y, Endo S, et al. Population pharmacokinetics of trastuzumab deruxtecan in patients with HER2-positive breast cancer and other solid tumors. *Clin Pharmacol Ther*. 2021;109:1314–25.
 37. Sundaramurthi P, Chadwick S, Narasimhan C. Physicochemical stability of pembrolizumab admixture solution in normal saline intravenous infusion bag. *J Oncol Pharm Pract*. 2020;26:641–6.
 38. Paccaly AJ, Migden MR, Papadopoulos KP, et al. Fixed dose of cemiplimab in patients with advanced malignancies based on population pharmacokinetic analysis. *Adv Ther*. 2021;38:2365–78.
 39. Yoo SH, Keam B, Kim M, et al. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. *ESMO Open*. 2018;3: e000332.
 40. Patil VM, Noronha V, Menon N, et al. Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemotherapy. *J Clin Oncol*. 2023 Jan 27;JCO2200980. <https://doi.org/10.1200/JCO.22.00980>. Online ahead of print.
 41. Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. *J Immunother Cancer*. 2016;4:1–11.
 42. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016;17:883–95.
 43. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncol*. 2017;18:31–41.
 44. Ray A, Sharma S, Sadasivam B. Carbovigilance: curtailing the global pharmaceutical carbon footprint. *Future Healthc J*. 2021;8: e683.
 45. Uyl-de Groot CA, Löwenberg B. Sustainability and affordability of cancer drugs: a novel pricing model. *Nat Rev Clin Oncol*. 2018;15:405–6.

Authors and Affiliations

Rob ter Heine¹ · Michel M. van den Heuvel² · Berber Piet² · Maarten J. Deenen^{3,4} · Anthonie J. van der Wekken⁵ · Lizza E. L. Hendriks⁶ · Sander Croes^{7,8} · Robin M. J. M. van Geel^{7,8} · Frank G. A. Jansman^{9,10} · Rogier C. Boshuizen¹¹ · Eric J. F. Franssen¹² · Arthur A. J. Smit¹³ · Daphne W. Dumoulin¹⁴ · Thijs H. Oude Munnink¹⁵ · Egbert F. Smit¹⁶ · Hieronymus J. Derijks^{1,17} · Cor H. van der Leest¹⁸ · Jeroen J. M. A. Hendriks¹⁹ · Dirk J. A. R. Moes²⁰ · Nikki de Rouw^{1,21}

¹ Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525GA Nijmegen, The Netherlands

² Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands

³ Department of Clinical Pharmacy, Catharina Hospital Eindhoven, Eindhoven, The Netherlands

⁴ Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands

⁵ Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

⁶ Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands

⁷ Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands

⁸ CARIM School for Cardiovascular Disease, Maastricht University Medical Center+, Maastricht, The Netherlands

⁹ Department of Clinical Pharmacy, Deventer Hospital, Deventer, The Netherlands

¹⁰ Unit of Pharmacotherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

¹¹ Department of Pulmonology, Deventer Hospital, Deventer, The Netherlands

¹² Department of Clinical Pharmacy, Onze Lieve Vrouwe Gasthuis Hospital AC, Amsterdam, The Netherlands

¹³ Department of Pulmonology, Onze Lieve Vrouwe Gasthuis Hospital AC, Amsterdam, The Netherlands

¹⁴ Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands

-
- ¹⁵ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- ¹⁶ Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands
- ¹⁷ Department of Pharmacy, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands
- ¹⁸ Department of Pulmonology, Amphia Hospital, Breda, The Netherlands
- ¹⁹ Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, The Netherlands
- ²⁰ Department of Clinical Pharmacology and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
- ²¹ Department of Clinical Pharmacy, Amphia Hospital, Breda, The Netherlands